With the start of 2019, conference season is in full swing, and now that Visikol has wrapped up SLAS, the team is getting ready for SOT in Baltimore. At this year’s SOT conference, Visikol will be showcasing its 3D cell culture models and assays for evaluating liver toxicity and studying liver disease pathologies.
This year’s conference in Baltimore will bring together over 315 companies from around-the-world and will host 80 scientific sessions and 2,100 presentations. Given SOT’s mission to bring together researchers from all facets of the toxicology research space, Visikol will feature its OpenLiver™ 3D cell culture model initiative that it recently launched with Biopredic International. As a leader in 3D cell culture assays, Visikol has launched the OpenLiver initiative to provide researchers with access to open source liver 3D cell culture models of varying complexities such that consensus surrounding appropriate model choice for evaluating mechanisms of toxicity and studying liver-related diseases (e.g. NASH, NAFLD) may be generated.
“By offering all the culture protocols and material sourcing information for our models through this OpenLiver initiative, we hope to enable researchers across the pharmaceutical and biotech community to more easily compare results within and between labs. We want to get everyone on the same page with the types of models that are being used for disease modeling and liver toxicity questions so that multiple labs can compare results and the field can establish consensus,” described Visikol Director of In Vitro Studies Dr. Erin Edwards. During the conference, Visikol we be hosting a talk by Chief Science Officer Dr. Thomas Villani titled Building Consensus in the Liver 3D Cell Culture Field Through Open Source Models. The talk will take place on 3/11 from 9-10:00 AM in room 339.
In this session, Visikol will discuss how it has developed open source liver 3D cell culture models for use in routine toxicity studies as well as more complex investigations into disease pathology, beginning with an in-depth discussion of the OpenLiver HepaRG™ NP 3D model. Additionally, participants will learn how cost, throughput, and in vivo relevancy can be optimized by varying the complexity of liver 3D cell culture models implemented.
Additionally, Visikol will be presenting a poster at SOT this year titled Complete Characterization of Cell Death in 3D Cell Culture Models for Toxicity Profiling (3074/ P611) on 3/13. To discuss your next research project, stop by booth 3225.